45845PAB4
Intercept Pharmaceuticals Inc
Could not find a ticker for this position, may be a filing error
A biopharmaceutical company that develops medicines for chronic liver diseases, including Ocaliva, a treatment for primary biliary cholangitis, a rare condition where bile ducts progressively damage the liver. Founded in 2002, the company's name reflects its mission to 'intercept' the march of liver disease. The Italian firm Alfasigma acquired it in 2023.
CONVERTIBLEUnderlying: ICPTCUSIP: 45845PAB4HealthcareUS1 derivative reporter
2.00% Convertible Senior Notes due 2026
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
